HELP YOUR PATIENTS OBTAIN ACCESS TO VISUDYNE®*

Ordering made easy:

CALL
Besse Medical **1 (888) 767-7123** to order VISUDYNE®

CONFIRM
that you have an existing account

PLACE
an order and it will be shipped the next day

First-time prescribers of VISUDYNE® can register with Besse Medical by signing up for an account

CREATE ACCOUNT

Patient assistance program*

FOCUS ON ACCESS™ (FOA) helps eligible patients secure access to VISUDYNE® and offers the following services*:

- Reimbursement information on insurance coverage availability for VISUDYNE®*
- Patient assistance for eligible patients without nsurance coverage or f the product s not covered by their insurance plan*

*Terms and conditions apply and can be found on the FOA enrollment form Please be sure to share eligibility criteria with your patients Bausch + Lomb does not guarantee coverage or reimbursement for the product

Printable resources for your patients:

ENROLLMENT FORM
Download the FOA savings program enrollment form for your patients

FOA CARD
Print FOA information card for your patients

For information on reimbursement and patient assistance services
Call the FOCUS ON ACCESS™ Hotline: 1 (866) 272-8838
(Monday-Friday, 9 AM to 5 PM EST)

Resources are available for your patients

Indication

VI UDYNE® (verteporf n for nject on) therapy s nd cated for the treatment of pat ents w th predom nantly class c subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

Important Safety Information

- VISUDYNE® (verteporfin for injection) is contraindicated for patients with porphyria or known hypersensitivity to any component of this preparation.
- Standard precautions should be taken during infusion of VISUDYNE® to avoid extravasation,

- A free-flowing intravenous (IV) line should be established before starting VISUDYNE® infusion and the line should be carefully monitored.
- Due to the possibly fragility of vein walls of some elderly patients, it is strongly recommended that the largest arm vein possible preferably the antecubital be used for injection
- Small veins in the back of the hand should be avoided.

- Extravasation of VISUDYNE®, especially if the affected area is exposed to light, can cause severe pain, inflammation, swelling or discoloration at the injection site. If extravasation does occur, the infusion should be stopped immediately The extravasation area must be thoroughly protected from direct light until swelling and discoloration have faded in order to prevent the occurrence of local burn, which could be severe. Cold compresses should be applied to the injection site. Oral medication for pain relief may be administered.
- Following injection with VISUDYNE®, care should be taken to avoid exposure of skin or eyes to direct sunlight or bright indoor light for 5 days. If emergency surgery is necessary within 48 hours after treatment, as much of the internal tissue as possible should be protected from intense light.
- Patients who experience severe decrease of vision of 4 lines or more within 1 week after treatment should not be retreated, at least until their vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by the treating physician.
- The most frequently reported adverse events (occurring in approximately 10%-30% of patients) were injection site reactions (including pain, edema, inflammation, extravasation, rashes, hemorrhage, and discoloration), and visual disturbances (including blurred vision, flashes of light, decreased visual acuity and visual field defects including scotoma)

Click here for full Prescribing Information for VISUDYNE®.

References: 1. VISUDYNE [package insert], Bausch & Lomb Incorporated